DE3689246D1 - Physiologisch aktives Polypeptid BUF-3. - Google Patents

Physiologisch aktives Polypeptid BUF-3.

Info

Publication number
DE3689246D1
DE3689246D1 DE86109029T DE3689246T DE3689246D1 DE 3689246 D1 DE3689246 D1 DE 3689246D1 DE 86109029 T DE86109029 T DE 86109029T DE 3689246 T DE3689246 T DE 3689246T DE 3689246 D1 DE3689246 D1 DE 3689246D1
Authority
DE
Germany
Prior art keywords
buf
physiologically active
active polypeptide
polypeptide
physiologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE86109029T
Other languages
English (en)
Other versions
DE3689246T2 (de
Inventor
Yuzuru Eto
Tomoko Tsuji
Satoshi Takano
Misako Takezawa
Yasunori Yokogawa
Hiroshiro Shibai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of DE3689246D1 publication Critical patent/DE3689246D1/de
Application granted granted Critical
Publication of DE3689246T2 publication Critical patent/DE3689246T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE3689246T 1985-07-03 1986-07-02 Physiologisch aktives Polypeptid BUF-3. Expired - Lifetime DE3689246T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP14631585 1985-07-03
JP17083985 1985-08-02
JP19727685 1985-09-06
JP28456385 1985-12-18

Publications (2)

Publication Number Publication Date
DE3689246D1 true DE3689246D1 (de) 1993-12-09
DE3689246T2 DE3689246T2 (de) 1994-05-26

Family

ID=27472707

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3689246T Expired - Lifetime DE3689246T2 (de) 1985-07-03 1986-07-02 Physiologisch aktives Polypeptid BUF-3.

Country Status (4)

Country Link
US (1) US5847078A (de)
EP (1) EP0210461B1 (de)
JP (1) JPH0637520B2 (de)
DE (1) DE3689246T2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis
ATE118351T1 (de) * 1988-05-31 1995-03-15 Biotech Australia Pty Ltd Wirkung von hormonen.
US5071834A (en) * 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
WO1992004913A1 (en) * 1990-09-13 1992-04-02 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
AU7668894A (en) * 1993-08-13 1995-03-14 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US5487895A (en) * 1993-08-13 1996-01-30 Vitaphore Corporation Method for forming controlled release polymeric substrate
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
ES2710048T3 (es) * 2004-07-23 2019-04-22 Acceleron Pharma Inc Anticuerpos antagonistas del receptor ActRII
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5415279B2 (ja) * 2006-12-18 2014-02-12 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩアンタゴニストおよび赤血球レベルを増加させるためのその使用
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
AU2008211007B2 (en) * 2007-02-01 2013-09-19 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) * 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
ES2756725T3 (es) * 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP3363453A1 (de) * 2008-06-26 2018-08-22 Acceleron Pharma Inc. Löslicher actriia als activin-actriia-antagonist zur verwendung in der behandlung von anämie oder knochenkrankheiten
PL3750552T3 (pl) 2008-08-14 2023-11-06 Acceleron Pharma Inc. Pułapki gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
AU2010204985A1 (en) * 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
BRPI1010587A2 (pt) 2009-06-08 2019-04-09 Acceleron Pharma Inc. métodos para aumentar adipócitos termogênicos
KR20190090049A (ko) 2009-06-12 2019-07-31 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
US20110129469A1 (en) * 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
WO2011063018A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
BR112015009948B1 (pt) 2012-11-02 2022-12-06 Celgene Corporation Uso de um inibidor de actrii
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028934A (ja) * 1983-07-25 1985-02-14 Green Cross Corp:The 細胞分化誘導物質
JPS60105621A (ja) * 1983-11-14 1985-06-11 Agency Of Ind Science & Technol 細胞の分化誘導作用を有する生理活性物質およびその製法
WO1986006076A1 (en) * 1985-04-18 1986-10-23 Biotechnology Australia Pty. Ltd. Recombinant inhibin
JP2652534B2 (ja) * 1985-04-18 1997-09-10 バイオテクノロジー・オーストラリア・ピーテイーワイ・リミテツド 組換えインヒビン
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US4798885A (en) * 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides

Also Published As

Publication number Publication date
EP0210461A2 (de) 1987-02-04
EP0210461B1 (de) 1993-11-03
EP0210461A3 (en) 1989-03-08
DE3689246T2 (de) 1994-05-26
JPH0637520B2 (ja) 1994-05-18
US5847078A (en) 1998-12-08
JPS62240700A (ja) 1987-10-21

Similar Documents

Publication Publication Date Title
DE3689246T2 (de) Physiologisch aktives Polypeptid BUF-3.
DK151985A (da) Humant fysiologisk aktivt polypeptid
DE3786767T2 (de) Neues Polypeptid.
NO863111D0 (no) Romaskin.
DE3686172T2 (de) Peptid-derivate.
DK496486A (da) Polypeptid
DK175487D0 (da) Farmaceutisk aktive 2-thiomethyl-substitueret-1,4-dihydro-pyridiner
DE3683186D1 (de) Rekombinantes humaninterleukin-1.
NO892294D0 (no) Polypeptidforbindelser.
DK551287D0 (da) Polypeptid
DK383985A (da) Polypeptid
DK354389D0 (da) Polypeptid
NO870533D0 (no) Terapeutisk aktive 3-alkoksy-2-aminopropylaminer.
DE3886517T2 (de) Menschlicher Prourokinase ähnliches Polypeptid.
NO853400L (no) Polypeptidvaksiner.
DE3586765T2 (de) Immunogenische hav-peptide.
ES555490A0 (es) Procedimiento de clonacion de factor humano viii-r.
DE3853743T2 (de) Rekombinanter menschlicher ADF.
DE3685636T2 (de) Lysozymbetreffende peptide.
DE3782199D1 (de) Biologisch aktive peptide tan-866.
ATE98990T1 (de) Menschlicher prourokinase aehnliches polypeptid.
NO874552D0 (no) Rekombinant human endotelial cellevekstfaktor.
NO875477D0 (no) Rekombinant alveolaert overflateaktivt protein.
ATE81531T1 (de) Biologisch aktive peptide tan-866.
IT8530687V0 (it) Sedia tuttiusi.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition